Premium
Tolerability of isavuconazole after posaconazole toxicity in leukaemia patients
Author(s) -
DiPippo Adam J.,
Rausch Caitlin R.,
Kontoyiannis Dimitrios P.
Publication year - 2019
Publication title -
mycoses
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.13
H-Index - 69
eISSN - 1439-0507
pISSN - 0933-7407
DOI - 10.1111/myc.12851
Subject(s) - tolerability , medicine , discontinuation , toxicity , posaconazole , adverse effect , dermatology , itraconazole , antifungal
Summary Background Posaconazole (PCZ) is widely used for prophylaxis or treatment of invasive fungal infections (IFIs) in leukaemia patients. However, issues with PCZ tolerability can result in treatment interruption. Isavuconazole (ISA) has a similar broad spectrum of activity to PCZ; however, real‐world data regarding the tolerability of ISA after PCZ toxicity are lacking. Objectives To describe the tolerability of ISA after PCZ toxicity in leukaemia patients. Patients/Methods We retrospectively assessed tolerability of ISA after PCZ toxicity in adult leukaemia patients (March 2015 to November 2017). We included all patients who received ≥7 days of ISA within 48 hours of PCZ discontinuation. Laboratory markers for liver toxicity were collected at three time points: prior to PCZ, at switch to ISA and after ISA therapy. Results We identified 23 such patients. Increased liver function tests (LFTs) were noted in 20 patients on PCZ, while three patients had Grade 3/4 QTc prolongation. No patient discontinued subsequent ISA due to toxicity. Grade 3/4 elevations in LFTs were decreased after changing to ISA (30% after PCZ vs 5% after ISA). No patient had significant QTc prolongation after switching to ISA. Conclusions Isavuconazole was well‐tolerated in patients discontinuing PCZ due to toxicity, with no patient discontinuing ISA due to toxicity.